Lupus & antiphospholipid syndrome
SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy
Authors' conclusion
This study confirmed the renoprotective effect of SGLT2 inhibitors in lupus mice, providing more evidence for non-immunosuppressive therapies to improve renal function in classic autoimmune kidney diseases such as LN.
Study context
- Population
- Lupus-prone MRL/lpr mice, SGLT2 knockout podocyte cell line, and patients with lupus nephritis (LN)9 patients with LN
- Comparison
- Empagliflozin (SGLT2 inhibitor) treatment in lupus-prone mice; SGLT2 inhibitors in patients with LN
Methodological detailsMRL/lpr lupus-prone mice, SGLT2 knockout podocyte cell line (CRISPR/Cas9), case series of patients with LN
- MRL/lpr lupus-prone mice
- SGLT2 knockout podocyte cell line (CRISPR/Cas9)
- Case series of patients with LN
Main finding
As reported in the abstract
- Empagliflozin-treated MRL/lpr mice: anti-dsDNA IgG, serum creatinine and proteinuria markedly decreased
- Glomerular and tubulointerstitial damage lessened by empagliflozin
- SGLT2 expression increased and colocalised with decreased synaptopodin in renal biopsies from LN patients and nephritic MRL/lpr mice
- Empagliflozin alleviated podocyte injury by attenuating inflammation and enhanced autophagy by reducing mTORC1 activity
Further findings
Proteinuria decrease in patients with LN on SGLT2 inhibitors (>2 months follow-up) · more than 2 months of follow-up
- Significant decrease in proteinuria
- 29.6% to 96.3%
- Estimated glomerular filtration rate (eGFR) relatively stable during treatment
Original publication
SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy. Ann Rheum Dis. Published 24 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →